Healthcare Profits: Assessing Company Sensitivity to Obamacare [View article]
How do explain the fact that US Pharma companies spend 2 - 3 times in BME (business development, advertising, marketing and lobbying) than R&D. Look at the income statement of any big pharma. The fact is that most drugs are me-too molecules marketed the hell out by armies of expensive sales reps.
Amgen: Lost in the Biotech Bargain Bin [View article]
I agree amgn is undervalued by any measure. It has massive free cash flows and a lot of cash (& equivalents) on the balance sheet. The low valuation is likely to attract predetors (i.e. Pfizer) which is sitting on a lot of cash as well.
Healthcare Profits: Assessing Company Sensitivity to Obamacare [View article]
The fact is that most drugs are me-too molecules marketed the hell out by armies of expensive sales reps.
Amgen: Lost in the Biotech Bargain Bin [View article]